Drug data last refreshed 12h ago · AI intelligence enriched 6d ago
HELIUM, USP is an inhaled gas product approved by the FDA in July 2021 for use via inhalation. The product is a respiratory gas with no specified pharmacologic mechanism of action or indication data provided. Patient use appears limited to specialized respiratory applications, though specific indications are not documented in available data.
Peak lifecycle stage indicates mature commercial operations, though limited spending data suggests a niche market with modest team expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
C2 Esophageal Squamous Epithelium Dysplasia
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
HELIUM, USP currently has zero linked job openings, indicating a small or stable team structure typical of niche gas product portfolios. Roles on this product would emphasize safety management and specialized physician engagement given the serious adverse event profile.